- Home
- NAAS vs ATRA Comparison
NAAS vs ATRA Comparison
Compare NAAS & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | ATRA |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 38.9M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NAAS | ATRA |
|---|---|---|
| Price | $3.35 | $8.09 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 18.2K | ★ 49.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $3.92 |
| 52 Week High | $4.54 | $19.15 |
Technical Indicators
Market Signals| Indicator | NAAS | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 41.98 |
| Support Level | $3.26 | $7.65 |
| Resistance Level | $3.47 | $9.11 |
| Average True Range (ATR) | 0.22 | 0.64 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 50.00 | 30.88 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).